D. Tabassum and K. Polyak, Tumorigenesis: it takes a village, Nature Reviews Cancer, vol.16, issue.8, pp.473-83, 2015.
DOI : 10.1007/s12094-014-1162-1

L. Lamberts, S. Williams, T. Van-scheltinga, A. , L. Hooge et al., Antibody Positron Emission Tomography Imaging in Anticancer Drug Development, Journal of Clinical Oncology, vol.33, issue.13, pp.1491-504, 2015.
DOI : 10.1200/JCO.2014.57.8278

O. Boerman and W. Oyen, Immuno-PET of Cancer: A Revival of Antibody Imaging, Journal of Nuclear Medicine, vol.52, issue.8, pp.1171-1173, 2011.
DOI : 10.2967/jnumed.111.089771
URL : http://jnm.snmjournals.org/content/52/8/1171.full.pdf

F. Kraeber-bodéré, C. Rousseau, C. Bodet-milin, C. Mathieu, F. Guérard et al., Tumor Immunotargeting Using Innovative Radionuclides, International Journal of Molecular Sciences, vol.55, issue.2, pp.3932-54, 2015.
DOI : 10.2967/jnumed.113.122630

H. Sun, C. England, R. Hernandez, S. Graves, R. Majewski et al., ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.18, issue.12, pp.259-275
DOI : 10.1093/intimm/dxl110

C. Divgi, N. Pandit-taskar, A. Jungbluth, V. Reuter, M. Gönen et al., Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial, The Lancet Oncology, vol.8, issue.4, pp.304-314, 2007.
DOI : 10.1016/S1470-2045(07)70044-X

C. Divgi, R. Uzzo, C. Gatsonis, R. Bartz, S. Treutner et al., Positron Emission Tomography/Computed Tomography Identification of Clear Cell Renal Cell Carcinoma: Results From the REDECT Trial, Journal of Clinical Oncology, vol.31, issue.2, pp.187-94, 2013.
DOI : 10.1200/JCO.2011.41.2445
URL : http://europepmc.org/articles/pmc5795663?pdf=render

E. Dijkers, J. Kosterink, A. Rademaker, L. Perk, G. Van-dongen et al., Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging, Journal of Nuclear Medicine, vol.50, issue.6, pp.974-81, 2009.
DOI : 10.2967/jnumed.108.060392
URL : http://jnm.snmjournals.org/content/50/6/974.full.pdf

R. Baum, V. Prasad, D. Müller, C. Schuchardt, A. Orlova et al., Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules, Journal of Nuclear Medicine, vol.51, issue.6, pp.892-899, 2010.
DOI : 10.2967/jnumed.109.073239
URL : http://jnm.snmjournals.org/content/51/6/892.full.pdf

K. Tamura, H. Kurihara, K. Yonemori, H. Tsuda, J. Suzuki et al., 64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer, Journal of Nuclear Medicine, vol.54, issue.11, pp.1869-75, 2013.
DOI : 10.2967/jnumed.112.118612
URL : http://jnm.snmjournals.org/content/54/11/1869.full.pdf

Y. Jauw, C. Menke-van-der-houven-van-oordt, O. Hoekstra, N. Hendrikse, D. Vugts et al., Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?, Frontiers in Pharmacology, vol.5, p.131, 2016.
DOI : 10.1038/nprot.2010.13
URL : http://journal.frontiersin.org/article/10.3389/fphar.2016.00131/pdf

G. Gebhart, L. Lamberts, Z. Wimana, C. Garcia, P. Emonts et al., Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial, Annals of Oncology, vol.2011, issue.4
DOI : 10.1200/JCO.2013.54.4999

I. Bahce, M. Huisman, E. Verwer, R. Ooijevaar, F. Boutkourt et al., Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer, EJNMMI Research, vol.21, issue.1, p.35, 2014.
DOI : 10.1016/j.ccr.2011.11.023
URL : https://ejnmmires.springeropen.com/track/pdf/10.1186/s13550-014-0035-5?site=ejnmmires.springeropen.com

C. Menke-van-der-houven-van-oordt, E. Gootjes, M. Huisman, D. Vugts, C. Roth et al., 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer, Oncotarget, vol.6, pp.30384-93, 2015.

S. Van-asselt, S. Oosting, A. Brouwers, A. Bongaerts, J. De-jong et al., Everolimus Reduces 89Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors, Journal of Nuclear Medicine, vol.55, issue.7, pp.1087-92, 2014.
DOI : 10.2967/jnumed.113.129056

M. Hollander, F. Bensch, A. Glaudemans, O. Munnink, T. Enting et al., TGF-?? Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET, Journal of Nuclear Medicine, vol.56, issue.9, pp.1310-1314, 2015.
DOI : 10.2967/jnumed.115.154401

K. Muylle, P. Flamen, D. Vugts, T. Guiot, G. Ghanem et al., Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab, European Journal of Nuclear Medicine and Molecular Imaging, vol.45, issue.11, pp.1304-1318, 2015.
DOI : 10.1089/cbr.2010.0812